Mitapivat
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications
Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease.
Journal: Hemoglobin
Published: June 09, 2026
Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease.
Journal: Blood. Red cells & iron
Published: March 11, 2026
Mitapivat for sickle cell disease: the time is ripe for a new therapy.
Journal: Annals of translational medicine
Published: February 17, 2026
SNH-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major.
Journal: Frontiers in pharmacology
Published: October 06, 2025
Discovery of 8-quinolinesulfonamide phenylimidazole-based PKM2 agonists for the prevention and delay of aortic dissection.
Journal: European journal of medicinal chemistry
Published: September 24, 2025
Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study.
Journal: Haematologica
Published: September 02, 2025
The ENERGIZE trial: Is mitapivat ready to take center stage in NTDT management?
Journal: Med (New York, N.Y.)
Published: August 08, 2025
Efficacy and safety of Mitapivat in sickle cell disease: a systematic review.
Journal: Expert opinion on pharmacotherapy
Published: July 07, 2025
Potent Fluorescent Probe for Target-Engagement Studies of Allosteric Pyruvate Kinase Modulators.
Journal: Angewandte Chemie (International ed. in English)
Published: June 26, 2025
Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review.
Journal: Blood reviews
Published: June 25, 2025
Last Updated: 06/30/2026